MabVax Therapeutics Holdings, Inc. and OPKO/Frost

CourtUnited States Bankruptcy Court, D. Delaware
DecidedJune 15, 2023
Docket19-10603
StatusUnknown

This text of MabVax Therapeutics Holdings, Inc. and OPKO/Frost (MabVax Therapeutics Holdings, Inc. and OPKO/Frost) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
MabVax Therapeutics Holdings, Inc. and OPKO/Frost, (Del. 2023).

Opinion

IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE

__________________________________________ ) In re: ) Chapter 11 ) MABVAX THERAPEUTICS ) Case No. 19-10603 (JTD) HOLDINGS, INC., et al., ) (Jointly Administered) ) Reorganized Debtors. ) Re: D.I. Nos. 483 & 538 __________________________________________)

MEMORANDUM OPINION AND ORDER

This matter began with a motion filed by preferred stockholders Ben Brauser, Dan Brauser, Greg Brauser, and Josh Brauser (collectively “Movants”) for entry of an order removing the Plan Administrator for the Second Amended Combined Disclosure Statement and Joint Plan of Liquidation for Debtors (“Motion to Remove” or “Complaint”).1 In response, the Plan Administrator filed a motion to enforce the confirmation order and dismiss the Motion to Remove (the “Motion to Dismiss”).2 Both motions were briefed, and oral argument was held on each.3 For the reasons set forth below, both motions are denied. BACKGROUND This case presents the unusual situation in which equity holders who were, pursuant to the Plan, expected to get nothing, are now, several years post-confirmation, likely to recover. This welcome development, however, comes with some complications.

1 D.I. 483, Motion to Remove Plan Administrator. As I indicated in a previous ruling, I am treating the Motion to Remove as a complaint because it seeks equitable relief which can only be obtained through an adversary proceeding. See D.I. 551 at 12 (Bench Ruling on Jurisdiction). 2 D.I. 538, Motion for Order (I) Enforcing Plan’s Exculpation and Injunction Provisions and Dismissing Movants’ Motion to Remove; and (II) Awarding Costs and Attorneys’ Fees. 3 See D.I. 484 (Objection to Motion to Remove); D.I. 544 (Objection to Motion to Dismiss); D.I. 545 (Reply); D.I. 551 (Transcript of 3/8/23 Hearing); D.I. 559 (Transcript of 5/4/23 Hearing). Pursuant to the plan and confirmation order,4 J. David Hansen (“Hansen”), the sole director of the debtors (“Debtors” or “MabVax”), was appointed as the plan administrator (“Plan Administrator”). The Plan provided that all equity interests would be extinguished, and owners would receive no distribution unless the Plan Administrator received, over time, enough

cash to pay general unsecured creditors in full. Among his other duties as Plan Administrator, Hansen is responsible for continuing the prosecution of a civil action commenced by Debtors in 2019 against several of their preferred shareholders in a matter captioned MabVax Therapeutics Holdings, Inc. v. Honig, et al., Case no. 37-2019-00018398-CU-SL-CTL, pending in the Superior Court for the State of California (the “California Litigation”). Defendants have filed a cross-complaint in that action against Hansen in his personal capacity. The Plan and Confirmation Order include provisions that prohibit distributions to any defendants in the California Litigation against whom judgment is entered. Movants are not named as defendants, but their father is. Movants hold both common and preferred shares of the Debtors. Hansen holds common shares, and his payment position is therefore subordinate to Movants.5

Debtors have settled with several defendants in the California Litigation, resulting in more than $12 million in proceeds to date.6 On May 26, 2022, the Court entered an order directing final payments be made to general unsecured creditors.7 Accordingly, any additional amounts received will now flow to subordinated claims, intercompany claims, and equity.

4 Second Amended Combined Disclosure Statement and Joint Plan of Liquidation (the “Plan”), D.I. 289; Findings of Fact, Conclusions of Law, and Order Approving and Confirming the Second Amended Combined Disclosure Statement and Joint Plan of Liquidation for Debtors (“Confirmation Order”), D.I. 327. 5 Motion to Remove at 7. 6 D.I. 441, 445. 7 D.I. 459. The possibility of an equity payout has given rise to Movants’ concerns regarding the appropriateness of Hansen’s continued role as the Plan Administrator. Specifically, they suggest that the Plan Administrator’s status as shareholder creates a conflict of interest with other interest holders, particularly preferred shareholders. For that reason, they ask the Court to

appoint a new Plan Administrator who is “completely disinterested, and capable of discharging fiduciary duties to all creditors and equity holders.” JURISDICTION AND VENUE The Court has subject matter jurisdiction over adversary proceedings pursuant to 28

U.S.C. § 1334(b). This matter is a core proceeding pursuant to 28 U.S.C. § 157(b)(2). Venue is proper pursuant to 28 U.S.C. § 1409(a).

LEGAL STANDARDS8 A motion to dismiss pursuant to Federal Rule of Civil Procedure 12(b)(6), made applicable to these proceedings by Federal Rule of Bankruptcy Procedure 7012, serves to test the sufficiency of the complaint, and a court’s role is to determine whether the plaintiff is entitled to offer evidence in support of its claims. Semerenko v. Cendant Corp., 223 F.3d 165, 173 (3d Cir. 2000); Paul v. Intel Corp. (In re Intel Corp. Microprocessor Antitrust Litig.), 496 F. Supp. 2d 404, 407 (D. Del. 2007) (citing Kost v. Kozakiewicz, 1 F.3d 176, 183 (3d Cir. 1993)). To survive a motion to dismiss, a plaintiff must allege well-pleaded facts with sufficient detail to “state a claim to relief that is plausible on its face.” Bell Ad. Corp. v.

8 Movants argue that the Motion to Remove is not an adversary proceeding and suggest that the Plan Administrator failed to cite authority for moving to dismiss the Motion to Remove. Objection, D.I. 544 at 7. As I explained in my bench ruling regarding jurisdiction, because Movants seek equitable relief, this matter should have been brought as an adversary proceeding rather than a motion creating a contested matter. D.I. 551 at 11-12; Federal Rules of Bankruptcy Procedure 7001(7). Rather than dismiss it outright, I informed the parties that for purposes of efficiency I will treat the Motion to Remove as a Complaint. While the Plan Administrator’s subsequent motion does not address the applicable standards, it is most appropriately interpreted as a motion to dismiss made pursuant to Rule 12(b)(6). Twombly, 550 U.S. 544, 570 (2007); Fowler v. UPMC Shadyside, 578 F.3d 203, 210 (3d Cir. 2009) (citing Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009)). Under this standard, “the tenet that a court must accept as true all of the allegations contained in a complaint is inapplicable to legal conclusions.” Iqbal, 556 U.S. at 678. The Third Circuit has adopted a two-part analysis

that courts must employ when deciding a motion to dismiss for failure to state a claim. Fowler, 578 F.3d at 210. “First, the factual and legal elements of a claim should be separated” with the reviewing court accepting “all of the complaint’s well-pleaded facts as true, but . . . disregard[ing] any legal conclusions.” Id. at 210-11.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
MabVax Therapeutics Holdings, Inc. and OPKO/Frost, Counsel Stack Legal Research, https://law.counselstack.com/opinion/mabvax-therapeutics-holdings-inc-and-opkofrost-deb-2023.